Novel Compounds and Mechanisms
NeuroQuest is a world leader in the research and patenting of a class of small-molecule, lipophilic compounds that demonstrate multiple mechanisms of action on nerve receptors, acting as antigonists on both sodium channels and TRP. These lipophilic compounds act quickly to inhibit nerve transmission while displaying low in vitro and in vivo toxicity and a high safety profile. The potential exists for both oral and topical dosage forms of these compounds. New chemical entities (NCEs), which are synthetic molecular analogs of proven, natural backbone structures, are in development. Several NCEs already show dramatically higher levels of activity than naturally occurring compounds and a demonstrated proof of relevance.
Research Strategy and Timeline
NeuroQuest is currently in the pre-clinical development stage, with medicinal chemistry focused on lead optimization of various new classes of small molecules that act upon TRP and sodium channels. NCE’s are being screened through world-class electrophysiology, cell-based and vertebrate assays with some compounds showing very high potency. NeuroQuest aims to develop several classes of small molecules over the next 24 months allowing for investigational new drug (IND) enabling studies to be initiated.
The commercialization risks for these compounds are greatly mitigated due to:
- strong first-in-field intellectual property,
- prior clinical evidence of the efficacy of similar classes of compounds
- exemplary safety profile of the naturally occurring compounds as determined by clinical use and depth of understanding of this class of compounds.
Potential technical challenges related to absorption characteristics, toxicity and metabolic profile are being addressed early in the drug development process.